

S2 Table. Stratum-specific effects of cinacalcet initiation on hospitalization (four-level stratification).

Type of Hospitalization	iPTH Subgroup	HR	95% CI	P-value
All-Cause	iPTH < 200 pg/mL	0.77	0.58, 1.03	0.080
All-Cause	200 ≤ iPTH < 300 pg/mL	0.83	0.65, 1.06	0.129
All-Cause	300 ≤ iPTH < 500 pg/mL	1.01	0.70, 1.45	0.961
All-Cause	iPTH ≥ 500 pg/mL	1.21	0.83, 1.77	0.318
Cardiovascular-Related	iPTH < 200 pg/mL	0.88	0.48, 1.61	0.667
Cardiovascular-Related	200 ≤ iPTH < 300 pg/mL	0.93	0.61, 1.41	0.719
Cardiovascular-Related	300 ≤ iPTH < 500 pg/mL	0.74	0.49, 1.11	0.143
Cardiovascular-Related	iPTH ≥ 500 pg/mL	0.89	0.49, 1.63	0.707
Infection-Related	iPTH < 200 pg/mL	0.36	0.14, 0.95	0.039
Infection-Related	200 ≤ iPTH < 300 pg/mL	0.89	0.46, 1.72	0.728
Infection-Related	300 ≤ iPTH < 500 pg/mL	1.24	0.53, 2.88	0.618
Infection-Related	iPTH ≥ 500 pg/mL	1.25	0.61, 2.53	0.543
Vascular Access-Related	iPTH < 200 pg/mL	0.60	0.30, 1.20	0.149
Vascular Access-Related	200 ≤ iPTH < 300 pg/mL	0.75	0.44, 1.27	0.280
Vascular Access-Related	300 ≤ iPTH < 500 pg/mL	1.44	0.74, 2.80	0.279
Vascular Access-Related	iPTH ≥ 500 pg/mL	1.18	0.61, 2.29	0.614

CI, confidence interval; HR, hazard ratio; iPTH, intact parathyroid hormone

HRs were adjusted for age, gender, cause of CKD, smoking status, duration of hemodialysis, history of hyperparathyroidism treatment, baseline comorbidities (diabetes and cardiovascular disease), baseline creatinine, baseline total protein, time-varying medications (VDRA, phosphate binders, iron supplements) and time-varying laboratory tests (Kt/V, iPTH, Ca, P, albumin, ferritin, iron, and hemoglobin).